Novo Nordisk A/S (NONOF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Bagsvaerd, Denmark. El CEO actual es Maziar Mike Doustdar.
NONOF tiene fecha de IPO 2010-05-07, 77,406 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $172.47B.
Novo Nordisk A/S is a global healthcare company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company operates through two primary segments: Diabetes and Obesity Care, which includes insulins, GLP-1 therapies, oral antidiabetic products, and obesity treatments; and Biopharmaceuticals, which focuses on haemophilia, growth disorders, and hormone replacement therapy. Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk maintains strategic collaborations with industry partners including Gilead Sciences and Lumen Bioscience to advance its pipeline in cardiometabolic disease treatments.
